Remdesivir News and Research

RSS

Super-resolution imaging of the human coronavirus genome during infection

Using high-throughput confocal super-resolution microscopy, scientists visualize the genomic material of the human coronavirus HCoV-229E.

9 Feb 2022

How SARS-CoV-2 infection progresses throughout the respiratory system

Researchers discuss the progression of SARS-CoV-2 infection throughout the respiratory epithelium.

9 Feb 2022

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

A new article reviewed the innate immune detection and signaling pathways that the host uses against SARS-CoV-2.

7 Feb 2022

UK's most vulnerable will soon be able to access second ground-breaking antiviral

Thousands of the country's most vulnerable will be able to access the UK's second ground-breaking antiviral - Pfizer's PF-07321332+ritonavir (Paxlovid) - from Thursday 10 February, the government has announced today.

28 Jan 2022

Potential therapy candidates for patients infected with the SARS-CoV-2 Omicron variant

Researcher discusses several promising therapeutic candidates that have been proposed for the treatment of patients infected with the Omicron variant.

28 Jan 2022

New trial tests the effectiveness of hyperimmune immunoglobulin for hospitalized COVID-19 patients

This scanning electron microscope image shows SARS-CoV-2 (round gold particles) emerging from the surface of a cell cultured in the lab. SARS-CoV-2, also known as 2019-nCoV, is the virus that causes COVID-19.NIAID

28 Jan 2022

Does remdesivir reduce mortality in moderately ill hospitalized patients with COVID-19?

A team of researchers performed a meta-analysis to investigate the use of remdesivir in the treatment of COVID-19.

26 Jan 2022

Hospitalized COVID-19 patients may derive modest benefit from convalescent plasma, study shows

Transfusions of blood plasma donated by people who have recovered from COVID-19 may help patients hospitalized with the virus, a new international study shows.

25 Jan 2022

Study explains why Omicron infections are less likely to cause severe disease

A new study by researchers from the University of Kent and the Goethe University Frankfurt shows that the SARS-CoV-2 Omicron variant is less effective than Delta at blocking a cellular defense mechanism against viruses, the so-called “interferon response”.

24 Jan 2022

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

In a recent study posted to the bioRxiv* preprint server, researchers test three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals authorized for emergency use by the United States Food and Drug Administration (FDA) for their in vitro potency against several SARS-CoV-2 variants, including the currently dominant Omicron train.

23 Jan 2022

Patient, beware: Some states still pushing ineffective covid antibody treatments

As the omicron variant completes its sweep across the U.S., states with scarce supplies of monoclonal antibody therapies continue to use two treatments that federal health officials warn no longer work against the highly contagious version of the virus that causes covid-19.

21 Jan 2022

PAXLOVID shown to be highly effective against all SARS-CoV-2 variants

A recent study, currently available on bioRxiv* preprint server, shows that a novel protease inhibitor known as nirmatrelvir has potent activity against Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also other variants evaluated in this paper – which supports its potential role in reducing the disease burden from coronavirus disease 2019 (COVID-19).

21 Jan 2022

SARS-CoV-2 Omicron infections milder in children compared to Delta

The clinical severity of COVID-19 was found to be lower in children younger than five years of age after the emergence of SARS-CoV-2 Omicron variant.

20 Jan 2022

Variants of SARS-CoV-2 and preventive strategies

A recent review article published in the journal Advanced Science reviewed the features of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants. Using a physical and materials science perspective, the review also summarizes the most significant variants of SARS-CoV-2 encountered to date as well as possible preventive strategies.

19 Jan 2022

The latest advancements in polymer-based nanotechnology approaches used to fight against SARS-CoV-2

A recent review discusses the engineering versatility of polymeric nanoparticles - making a good therapeutic alternative against coronavirus diseases.

19 Jan 2022

Macrodomains represent a unique target for pathogens with pandemic potential

In a new study published in the journal Pathogens, researchers have summarized the role of the macrodomain in viral replication and virulence and further reviewed the development of macrodomain inhibitors as antiviral agents.

18 Jan 2022

New findings support the routine use of remdesivir in hospitalized COVID-19 patients

Remdesivir, an antiviral drug used to treat COVID-19, increased the likelihood of clinical improvement in COVID-19 patients on low-flow oxygen or no oxygen, according to a new study authored by the Johns Hopkins University School of Medicine, the Johns Hopkins Bloomberg School of Public Health, HCA Healthcare, and Genospace.

18 Jan 2022

Topical antiseptic Acriflavine inhibits SARS-CoV-2 and other betacoronaviruses

A new study, published in the journal Cell Chemical Biology, has reported the discovery of acriflavine (ACF), an effective inhibitor of SARS-CoV-2. This drug is a mixture of trypaflavines (3,6-diamino-10-methylacridinium chloride and 3,6-diamino-3-methylacridinium chloride) and proflavine (3,6-diaminoacridine).

16 Jan 2022

Impact of post-exposure BNT162b2 prophylaxis against SARS-CoV-2 infections

In a new study, researchers determined evidence for post-exposure vaccination in reducing the mortality rate of COVID-19 and concluded that post-exposure prophylaxis successfully decreased SARS-CoV-2-associated death rates.

11 Jan 2022

Lab engineered human A549 lung cell model conducive for investigating SARS-CoV-2 antivirals

Researchers developed a human A549 lung epithelial cell-based model to probe SARS-CoV-2 replication.

9 Jan 2022

Remdesivir News and Research

Super-resolution imaging of the human coronavirus genome during infection

How SARS-CoV-2 infection progresses throughout the respiratory system

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

UK's most vulnerable will soon be able to access second ground-breaking antiviral

Potential therapy candidates for patients infected with the SARS-CoV-2 Omicron variant

New trial tests the effectiveness of hyperimmune immunoglobulin for hospitalized COVID-19 patients

Does remdesivir reduce mortality in moderately ill hospitalized patients with COVID-19?

Hospitalized COVID-19 patients may derive modest benefit from convalescent plasma, study shows

Study explains why Omicron infections are less likely to cause severe disease

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

Patient, beware: Some states still pushing ineffective covid antibody treatments

PAXLOVID shown to be highly effective against all SARS-CoV-2 variants

SARS-CoV-2 Omicron infections milder in children compared to Delta

Variants of SARS-CoV-2 and preventive strategies

The latest advancements in polymer-based nanotechnology approaches used to fight against SARS-CoV-2

Macrodomains represent a unique target for pathogens with pandemic potential

New findings support the routine use of remdesivir in hospitalized COVID-19 patients

Topical antiseptic Acriflavine inhibits SARS-CoV-2 and other betacoronaviruses

Impact of post-exposure BNT162b2 prophylaxis against SARS-CoV-2 infections

Lab engineered human A549 lung cell model conducive for investigating SARS-CoV-2 antivirals

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News